CME/CE Webinars

The premier issue highlights the fundamentals of biosimilar regulation and development in the US and recently released materials on biosimilars, Dr. Edward Li.

An 11-Minute Tutorial:
Dr. Edward Li discusses the fundamentals of “Biosimilar Regulation and Development in the US"

Listen to Dr. Li describe the similarities and differences between biosimilars and reference biologics, and review current FDA regulation guidance

Play

		Survey Question: On a scale of 1 to 100, if approved by the FDA, what is your interest in prescribing, dispensing or administering biosimilars in your practice setting?

Request a Live Meeting

Support available for Grand Rounds, Chapter Meetings, and other gatherings.

New & Noteworthy

Newsfeed
Infliximab-qbtx Approved by FDA
READ MORE
Newsfeed
First Trastuzumab Biosimilar, Ogivri, Approved by FDA
READ MORE
CME/CE Webinars
Biosimilars Summary Based on FDA Approval: Differences Between Biosimilars and Generics
READ MORE

Biosimilars Report Issue 1, Regulation and Development

An 11-Minute Tutorial:Dr. Edward Li discusses the fundamentals of “Biosimilar Regulation and Development in the US"

Survey Question: On a scale of 1 to 100, if approved by the FDA, what is your interest in prescribing, dispensing or administering biosimilars in your practice setting?

Request a Live Meeting

New & Noteworthy

Infliximab-qbtx Approved by FDA

First Trastuzumab Biosimilar, Ogivri, Approved by FDA

Biosimilars Summary Based on FDA Approval: Differences Between Biosimilars and Generics

An 11-Minute Tutorial:
Dr. Edward Li discusses the fundamentals of “Biosimilar Regulation and Development in the US"

Survey Question:
On a scale of 1 to 100, if approved by the FDA, what is your interest in prescribing, dispensing or administering biosimilars in your practice setting?